BR112012006149A2 - composição farmacêutica. - Google Patents

composição farmacêutica.

Info

Publication number
BR112012006149A2
BR112012006149A2 BR112012006149A BR112012006149A BR112012006149A2 BR 112012006149 A2 BR112012006149 A2 BR 112012006149A2 BR 112012006149 A BR112012006149 A BR 112012006149A BR 112012006149 A BR112012006149 A BR 112012006149A BR 112012006149 A2 BR112012006149 A2 BR 112012006149A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
reducing
combination
agent
ccbs
Prior art date
Application number
BR112012006149A
Other languages
English (en)
Inventor
Alessandro Blé
Angelo Guglielmotti
Beatrice Garrone
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of BR112012006149A2 publication Critical patent/BR112012006149A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

a presente invenção refere-se a uma composição farmacêutica compreendendo uma combinação de derivado de 1-benzil-3-hidroximetilindazol, um agente redutor de pressão selecionado dentre os inibidores de ace, os inibidores de renina, arbs e ccbs, e/ou um agente redutor de colesterol selecionado dentro os derivados da estatina. a combinação mostou uma atividade aditiva e sinergística em reduzir os níveis de mcp-1, assim significativamente melhorando a inibição da resposta inflamatória e consequentemente reduzingo as complicações que ocorrem nos pacientes sofrendo das doenças inflamatórias.
BR112012006149A 2009-09-23 2010-09-03 composição farmacêutica. BR112012006149A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425368 2009-09-23
PCT/EP2010/062979 WO2011036047A1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Publications (1)

Publication Number Publication Date
BR112012006149A2 true BR112012006149A2 (pt) 2016-06-28

Family

ID=41722750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006149A BR112012006149A2 (pt) 2009-09-23 2010-09-03 composição farmacêutica.

Country Status (25)

Country Link
US (1) US9492542B2 (pt)
EP (1) EP2480224B1 (pt)
JP (2) JP2013505278A (pt)
KR (1) KR101774402B1 (pt)
CN (1) CN102573827B (pt)
AR (1) AR078307A1 (pt)
AU (1) AU2010297405B2 (pt)
BR (1) BR112012006149A2 (pt)
CA (1) CA2760180C (pt)
CY (1) CY1119125T1 (pt)
DK (1) DK2480224T3 (pt)
EA (1) EA021485B1 (pt)
ES (1) ES2637024T3 (pt)
GE (1) GEP20146067B (pt)
HR (1) HRP20171209T1 (pt)
HU (1) HUE033102T2 (pt)
IL (1) IL218001A (pt)
LT (1) LT2480224T (pt)
MX (1) MX347957B (pt)
PL (1) PL2480224T3 (pt)
PT (1) PT2480224T (pt)
SG (2) SG10201405408YA (pt)
SI (1) SI2480224T1 (pt)
UA (1) UA108742C2 (pt)
WO (1) WO2011036047A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2262778T (pt) 2008-03-07 2019-11-19 Acraf Derivados de 1-benzil-3-hidroximetilindazolo e utilização dos mesmos no tratamento de doenças baseadas na expressão de mcp-1, cxcr1 e p40
JP5509102B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US11221321B2 (en) * 2019-05-29 2022-01-11 Imam Abdulrahman Bin Faisal University Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88400C (fi) 1984-08-06 1993-05-10 Upjohn Co Foerfarande foer framstaellning av renin inhiberande peptider
MY103189A (en) 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
CA2023099A1 (en) 1989-09-04 1991-03-05 Quirico Branca Amino acid derivatives
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
TW198712B (pt) 1991-04-17 1993-01-21 Hoffmann La Roche
IT1253703B (it) 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
SE9600120D0 (sv) 1996-01-15 1996-01-15 Astra Ab Novel medical use
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
US20030073705A1 (en) 2001-05-14 2003-04-17 Shahnaz Shahinfar Method of treatment
US20030060501A1 (en) 2001-09-19 2003-03-27 Francois Mach Facilitating tissue grafts with statins (HMG-COa reductase inhibitors)
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20070060549A1 (en) 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
CN101052402A (zh) 2004-10-29 2007-10-10 兴和株式会社 肾小球疾病治疗剂
CN101365438A (zh) 2006-02-07 2009-02-11 持田制药株式会社 预防中风复发的组合物
WO2008084504A2 (en) 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
CA2679446C (en) * 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5509102B2 (ja) 2008-03-07 2014-06-04 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用
PL2254870T3 (pl) * 2008-03-07 2016-07-29 Acraf Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
PT2262778T (pt) 2008-03-07 2019-11-19 Acraf Derivados de 1-benzil-3-hidroximetilindazolo e utilização dos mesmos no tratamento de doenças baseadas na expressão de mcp-1, cxcr1 e p40

Also Published As

Publication number Publication date
CY1119125T1 (el) 2018-02-14
ES2637024T3 (es) 2017-10-10
JP6122470B2 (ja) 2017-04-26
IL218001A0 (en) 2012-04-30
UA108742C2 (uk) 2015-06-10
IL218001A (en) 2015-10-29
US20120220636A1 (en) 2012-08-30
CA2760180A1 (en) 2011-03-31
SG178414A1 (en) 2012-03-29
PT2480224T (pt) 2017-07-18
KR20120090988A (ko) 2012-08-17
AU2010297405A1 (en) 2012-03-01
SI2480224T1 (sl) 2017-10-30
MX347957B (es) 2017-05-16
KR101774402B1 (ko) 2017-09-04
CN102573827A (zh) 2012-07-11
LT2480224T (lt) 2017-08-25
WO2011036047A1 (en) 2011-03-31
GEP20146067B (en) 2014-03-25
CA2760180C (en) 2017-07-25
HRP20171209T1 (hr) 2017-10-20
SG10201405408YA (en) 2014-10-30
AR078307A1 (es) 2011-10-26
US9492542B2 (en) 2016-11-15
EP2480224B1 (en) 2017-05-24
PL2480224T3 (pl) 2017-10-31
CN102573827B (zh) 2016-08-31
JP2013505278A (ja) 2013-02-14
HUE033102T2 (en) 2017-11-28
EA201270449A1 (ru) 2012-08-30
AU2010297405B2 (en) 2016-05-26
EP2480224A1 (en) 2012-08-01
MX2012003485A (es) 2012-04-19
EA021485B1 (ru) 2015-06-30
DK2480224T3 (en) 2017-09-04
JP2016028026A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
PH12013501319A1 (en) Fatty acid acetylated salicylates and their uses
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
IN2012DN02661A (pt)
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
BR112012018022A2 (pt) inibição de sinalização axl em terapia antimetastática.
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
BR112012024618A2 (pt) usos de inibidores de dgat1
BR112013006673A2 (pt) produtos terapêuticos para câncer de mama
WO2011051966A3 (en) Pharmaceutical compositions for treatment/prophylaxis of non-alcoholic fatty liver disease
BR112012006149A2 (pt) composição farmacêutica.
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2013166177A3 (en) Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
PH12015502679A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]